Acumen Pharmaceuticals Inc. (NASDAQ: (ABOS) stock plunged by 2.43% at last close while ABOS stock price declines by 5.34% in the pre-market trading session even though the company has not provided any news regarding this downfall. Acumen is a clinical-stage pharmaceutical business established in Charlottesville, Virginia, with clinical activities in Carmel, Indiana. It is developing a revolutionary disease-modifying method to cure Alzheimer’s disease.
ABOS stock’ Recent Past Development
The first patient in INTERCEPT-AD which is a Phase 1 placebo-controlled, single- and multiple-dose clinical study of ACU193, has been dosed. It is a monoclonal antibody that preferentially attacks toxic amyloid-beta oligomers (AOs) for the cure of early Alzheimer’s disease.
ACU193 is a monoclonal antibody (mAb) that was identified and designed depending on its specificity of targeting AβOs. AβOs are powerful neurotoxins that attach to neurons, block synaptic function, and cause neurodegeneration. ACU193 intends to effectively address the major root cause of the neurodegenerative process in AD by selectively targeting toxic AβOs.
Daniel O’Connell, President, and CEO of Acumen stated,
They are ecstatic to announce that ACU193 has reached its first clinical development goal. The recent pace and the scope of scientific innovation being used in Alzheimer’s research give them hope. ACU193 has the potential to fulfill the significant unmet needs of those living with Alzheimer’s disease, according to them.
Eric Siemers MD, Chief Medical Officer for Acumen commented,
They’re all really excited to see how ACU193 performs in the INTERCEPT-AD experiment. The purpose of this Phase 1 clinical study is to prove that ACU193 is safe and effective, as well as to assess pharmacokinetics and target engagement. They’ve also included usual clinical outcomes for Alzheimer’s disease, as well as exploratory tests. They believe ACU193 has the ability for increased efficacy and safety relative to other monoclonal antibodies in development because of its unique mode of action.
